Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan

Table 2 Virological responses

HCV RNA < LLOD	FIB-4 ≤ 3.25 (N = 635), N/N (%)	FIB-4 > 3.25 (N = 188), N/N (%)	p value
End of treatment
ETR (PP)	609/612 (99.5)	183/183 (100)	0.79
Lost to follow-up	23	5
After treatment
SVR (EP)	593/635 (93.4)	172/188 (91.5)	0.47
SVR (PP)	593/598 (99.2)	172/172 (100)	0.51
Reason for non-SVR_, N
Relapse	2	0
Nonresponse	3	0
Lost to follow-up	37	16

EP, evaluable population; ETR, end-of-treatment response; PP, per protocol; SVR, sustained virological response

ISSN: 1471-230X